<- Go home

Added to YB: 2026-05-12

Pitch date: 2026-05-10

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

-6.46%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 366.1M

Pitch Price

CAD 19.51

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.18

P/E

12.09

EV/Sales

7.07

Sector

Pharmaceuticals

Category

growth

Show full summary:
Cipher Pharmaceuticals Q1 2026 Update – CPH.to

CPH.TO (earnings): Q1 rev $12.5M (+4% YoY), adj EBITDA $7.7M (+25% YoY), 62% EBITDA margin (+10%). Natroba rev $6.9M (+3%), gross margin 87% vs 77%. DTC launch underway, driving higher net pricing via commercial payer mix. Debt-free, NCIB renewed, evaluating upsized credit facility for M&A. MOB-015 U.S. Ph3 potential catalyst. 12.1x EV/EBITDA, 13.1x EV/FCF.

Read full article (2 min)